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ABSTRACT: The European Centre for Disease Prevention and Control (ECDC) and the European
Respiratory Society (ERS) jointly developed European Union Standards for Tuberculosis Care
(ESTC) aimed at providing European Union (EU)-tailored standards for the diagnosis, treatment
and prevention of tuberculosis (TB).
The International Standards for TB Care (ISTC) were developed in the global context and are not
always adapted to the EU setting and practices. The majority of EU countries have the resources
and capacity to implement higher standards to further secure quality TB diagnosis, treatment and
prevention. On this basis, the ESTC were developed as standards specifically tailored to the
EU setting.
A panel of 30 international experts, led by a writing group and the ERS and ECDC, identified and
developed the 21 ESTC in the areas of diagnosis, treatment, HIV and comorbid conditions, and
public health and prevention. The ISTCs formed the basis for the 21 standards, upon which
additional EU adaptations and supplements were developed.
These patient-centred standards are targeted to clinicians and public health workers, providing
an easy-to-use resource, guiding through all required activities to ensure optimal diagnosis,
treatment and prevention of TB. These will support EU health programmes to identify and develop
optimal procedures for TB care, control and elimination.
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W
ith more than 80,000 tuberculosis (TB)
cases notified in the European Union and
European Economic Area (EU/EEA)
Member States in 2009 (EU/EEA countries com-
prise Austria, Belgium, Bulgaria, Cyprus, Czech
Republic, Denmark, Estonia, Finland, France,
Germany, Greece, Hungary, Iceland, Republic of
Ireland, Italy, Latvia, Liechtenstein, Lithuania,
Luxembourg, Malta, The Netherlands, Norway,
Poland, Portugal, Romania, Slovakia, Slovenia,
Spain, Sweden, UK; while Switzerland is not in
the EEA, Swiss nationals have the same rights as
EEA nationals), TB continues to be a priority public
health challenge in this setting. Although several
EU/EEA countries are progressing towards sus-
tained low levels of TB incidence, the contrasts in
TB disease burden remain great within the sub-
region [1]. Drug-resistant TB and multidrug-resis-
tant TB (MDR-TB) pose a specific public health
threat in some countries. Furthermore, assessing
the prevalence of HIV co-infection among TB cases
is still compromised by suboptimal reporting in
several countries [1–3].
While EU/EEA countries adopted the key princi-
ples of TB control and elimination through the
European-specific, consensus-based documents
born within the Wolfheze initiative [1], a uniform
set of guidelines summarising the minimum
standards clinicians and healthcare workers should
look at to guide their practice, was still lacking. The
recent finalisation of the International Standards for
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Tuberculosis Care (ISTC) [1–4], developed in 2009 by 50 experts
from 15 countries to include the perspectives of several organi-
sations and international societies (which endorsed them for uni-
versal use), offered the opportunity to tackle this gap in the EU.
The ISTC [1–4] prescribe a widely accepted level of TB care
which guides all healthcare providers and clinicians, both
public and private, in achieving optimal standards in mana-
ging patients who have, or are suspected of having, active TB.
The 21 ISTCs [4] are organised into 4 sections: 1) standards
for diagnosis, 2) standards for treatment, 3) standards for
addressing HIV co-infection and other comorbid conditions
and 4) standards for public health.
The standards, seen as ‘‘a living document that will be revised
as technology, resources and circumstances change’’, are
designed to complement existing national or international
guidelines, and are consistent with World Health Organization
(WHO) definitions and recommendations.
The specific characteristics of the EU/EEA Member States
which justify the need to develop standards specifically
tailored to the European context are [1, 2]:
1) The majority of EU/EEA countries have a low incidence of
TB; however, a heterogeneous setting exists with a number of
Member States having high and intermediate TB levels, with
varying levels of MDR-TB and TB-HIV co-infection. Also a
number of countries border non-EU countries with a higher TB
and MDR-TB burden.
2) TB services are fully integrated and merged within the
health system in the majority of EU/EEA countries. This
presents peculiarities in allocating responsibilities for the
optimal delivery of TB care.
3) The EU/EEA countries have a long-established tradition of
TB control that has evolved over past decades. New tools and
high standards of diagnosis and care are often implemented in
EU/EEA countries.
4) The EU/EEA countries are committed to pursue elimination
of TB, sharing a common platform based on the Wolfheze
documents; the Framework action plan to fight TB in the EU;
Progressing towards TB elimination, and the European Centre
of Disease Prevention and Control (ECDC)-driven surveillance
system [5–14].
In spite of efforts to introduce ISTCs among EU/EEA
healthcare providers (including clinicians), their implementa-
tion has been suboptimal. A tailored set of standards present
the potential to improve acceptability among clinical networks.
METHODS
A collaborative process, jointly led by the ECDC and the
European Respiratory Society (ERS), was initiated to adapt the
ISTCs to the EU/EEA setting and to develop the EU Standards
for Tuberculosis Care (ESTC). While ERS has taken the lead in
developing the clinically-related standards, ECDC has done
the same for the public health standards.
A panel of more than 30 experts was convened representing
the ERS and other international societies (American Thoracic
Society (ATS), ECDC, national TB programmes and civil
society (affected communities)) and organisations (WHO,
International Union against Tuberculosis and Lung Diseases
(the Union, Europe Region) and KNCV Tuberculosis Founda-
tion). Within this group, a writing committee consisting of
eight experts was identified to lead the consensus and writing
process of the document.
A non-systematic review of the evidence relevant for the
development of the ESTC was performed (including the peer-
reviewed manuscripts and systematic reviews/meta-analyses
included in the ISTC document and those published after the
second edition of the ISTC) to support the development of the
document.
A Delphi process was performed to define the list of standards
based on prior evidence [1, 2].
The panel of experts was asked to assign priorities to the first
draft of 45 proposed standards and to complete the literature
synopsis of the standards-supporting evidence with a score
ranging from 5 (high relevance) to 1 (low relevance). Based on
the results of the Delphi process, the draft concept of the
standards and the literature synopsis were completed and
circulated within the panel of experts for two rounds of review,
comments and additions. Consensus was at this stage reached
to formulate the standards around the existing four sections of
the ISTCs (diagnosis, treatment, clinical management of TB/
HIV and comorbidities, and public health and prevention). The
Delphi exercise was completed by 85% of the panel of experts,
with the main score per area being high, ranging between 4.04
and 4.74. The literature synopsis was also scored and 21
references were added to the 97 initially proposed.
The ESTC have been specifically developed to complement
the ISTCs and other existing guidelines, being based mainly, but
not exclusively, on the existing gaps in case management that
were identified in a recent European MDR-TB case management
survey as well as the survey of TB surveillance systems in low-
incidence countries, including countries of the EU/EEA [2].
In the process of developing the standards and reaching a
consensus, the panel of experts further identified the need and
added value of complementing the standards with supporting
enablers. These are aimed as a resource for policy makers,
clinicians, public health workers and stakeholders as a support
to identify resources and suggestions on how best to adopt,
adapt, introduce and implement the ESTC in their setting.
The concept of ESTC was first presented and discussed in a
symposium at the 2010 ERS Congress in Barcelona. Three
working meetings between ERS and ECDC experts and a vis-a`-
vis meeting of the expert writing committee were organised in
2011, preceding circulation of the draft document to the entire
expert panel. The draft ESTC document was presented and
discussed further during a symposium at the September 2011
ERS conference in Amsterdam and finalised in October 2011
before going through an official clearance process of the ERS
and the ECDC.
HOW TO READ THE DOCUMENT
Under four sections (diagnosis, treatment, HIV and comorbid-
ities, and public health), 21 standards are defined, which
correspond to those of the ISTC. Using the ISTC as a basis, the
EU Standards for TB care were developed and are listed as either:
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1) ‘‘Valid’’: the corresponding ISTC has been maintained and is
considered the EU standard. When an ISTC was maintained as
‘‘valid’’, none-to-minimal wording will have been adapted to
update to the EU-definition; i.e. smear-positive cases are now
defined as culture-positive in diagnosis standards. Otherwise
the original wording from the ISTC has been maintained in
order to ensure consistency and comparability between the
two documents.
2) ‘‘Valid with an EU-adapted supplement’’: the corresponding
ISTC has been maintained but with an additional EU
component that covers the minimal requirement for standards
in the EU; as defined by the expert groups and EU definitions.
3) ‘‘Replaces standard x’’: the corresponding ISTC has been
modified extensively in order to fit in with EU definitions and
requirements.
When necessary, notes are listed after each standard to further
define and explain specific components that the expert group
deemed important to clarify. Where a standard replaces an
ISTC, the original wording of the ISTC is listed under the
heading Replaced ISTC at the end of the document.
STANDARDS FOR TB DIAGNOSIS
Standard 1 (replaces ISTC 1*)
All persons presenting with signs, symptoms, history or risk
factors compatible with TB should be evaluated for pulmonary
and/or extrapulmonary TB.
Notes
1) The most common symptoms of pulmonary TB are
persistent cough with or without sputum production for more
than 2–3 weeks [4], while haemoptysis (blood in mucus) is
more rare. Respiratory symptoms can be accompanied by
fever, night sweats and weight loss. These signs and symptoms
are common in a wide range of respiratory conditions
including acute respiratory infections and acute exacerbation
of chronic obstructive pulmonary disease. It is also possible for
patients to present with no signs and symptoms of disease [15].
For extrapulmonary TB, TB organ-specific signs and symptoms
may occur.
2) It is important to investigate the history of the patient with
regard to TB. For example, history of TB in the family context,
history of previous contact with TB and previous TB diagnosis
and/or treatment, and any condition attenuating the host
immune system [4] are common risk factors for TB that should
be considered as relevant to guide the correct diagnosis.
3) In the EU setting, TB is not the leading cause of persistent
cough and, thus, cough is not the leading sign or symptom of
TB disease. Based on its expert knowledge and experience of
the EU setting and the current evidence [16] the expert group
therefore adapted this first standard to better describe a patient
who should be evaluated for TB disease in the EU-setting.
Standard 2 (replaces ISTC 2#)
All patients (adults, adolescents and children who are capable
of producing sputum) suspected of having pulmonary TB
should have at least two sputum specimens submitted for
microscopic examination, culture and drug susceptibility
testing (DST) in a quality-assured laboratory. When possible,
at least one early morning specimen should be obtained. In
countries, settings or populations in which MDR-TB is
suspected in a patient, rapid testing for the identification of
rifampicin- and isoniazid-resistance, using validated tools in a
quality-assured laboratory, should be performed.
Notes
1) Based on the EU/EEA practice and definitions [13, 14, 17],
quality-assured DST should be performed on all diagnosed TB
patients to rule out drug resistance [5–14]. This should follow
international standards and guidelines with regard to methods
used and drug concentrations, for testing of first- and second-
line drugs [8–10]. Samples sent for bacteriological examina-
tions (sputum smear, culture, DST and new molecular
methods) should be addressed to a mycobacteriology labora-
tory which implements optimal laboratory practices and
quality-assured procedures according to European and inter-
national recommendations [8–10, 18–21].
2) There are two categories of risk factors for MDR-TB: patient
risk factors and setting risk factors [22, 23], which need to be
considered when assessing the risk for MDR-TB [24]. Previous
contact with MDR-TB patients and previous history of TB
treatment are two key patient risk factors for MDR-TB.
Originating from settings with a high prevalence of MDR-TB
(e.g. Eastern European countries) are further relevant risk
factors for MDR-TB [18, 25–28].
3) Countries should transform the process of risk assessment
into guidelines and adapt them to their national needs [4, 7].
4) Quality bacteriological diagnosis includes the WHO
recommended rapid molecular assays, which should be
performed as early as possible (ideally on the same day as
diagnosis) within evidence-based diagnostic algorithms and
guidelines. Currently available methods are the automated
real-time nucleic acid amplification technology for rapid and
simultaneous detection of Mycobacterium tuberculosis and
rifampicin resistance, and the line probe assays for rapid M.
tuberculosis detection and rifampicin resistance or rifampicin
and/or isoniazid resistance testing [19, 29, 30]. These
approaches allow immediate identification of M. tuberculosis
and rifampicin resistance and/or MDR-TB (rifampicin resis-
tance can be considered a proxy of MDR-TB) [19–21, 29, 30, 31].
All molecular diagnostic results must be confirmed further by
culture-based DST. All identified MDR-TB cases should be
managed by specialised centres directly upon diagnosis and a
second independent molecular test with a different technology
should be performed to confirm the rapid diagnosis [32–37].
5) The choice of molecular methods for the rapid identification
of rifampicin resistance and isoniazid resistance should be that
of WHO-endorsed rapid diagnostic assays [29].
6) Optimal, clear and direct communication between the
laboratory experts and clinicians is essential to obtain the
optimal link of diagnosis and choice of treatment. The clinician
needs to be informed whether the laboratory performs DST for
second-line drugs and on which drugs. Furthermore, they
need to be informed on whether proficiency testing (external
quality assurance) for all provided DST methods is imple-
mented according to evidence-based guidelines. The clinician
All persons presenting with signs, symptoms, history or risk
factors compatible with TB should be evaluated for pulmonary
and/or extrapulmonary TB.
All patients (adults, adolescents and children who are capable
of producing sputum) suspected of having pulmonary TB
should have at least two sputum specimens submitted for
microscopic examination, culture and drug susceptibility
testing (DST) in a quality-assur d laboratory. When possible, at
least one early morning specimen should be obtained. In
countri s, settings or populatio s in which MDR-TB is
suspected in a patient, rapid esting for the entification of
rif mpicin- an isoni zid-re istance, using validated tools in a
quality-assured laboratory, should be performed.
G.B. MIGLIORI ET AL. ECDC/ERS TASK FORCE REPORT
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 39 NUMBER 4 809
needs to ensure that the bacteriological sample undergoes
first- and second-line DST according to evidence-based guide-
lines [8–10, 18, 38].
7) Based on feasibility and cost-effectiveness analyses, the WHO
and the ISTC recommend the collection of at least two sputum
samples for diagnosis. Given that the collection of a third sample
has been shown to increase the diagnostic yield by 2–3%, EU/
EEA countries may decide to maintain the previous recommen-
dation of collecting three sputum samples on the same day (not
necessarily on consecutive days) [4, 39, 40].
8) It is essential to obtain quality sputum samples in order to
ensure quality and reliable bacteriological testing of the sample
[4, 39]. This includes ensuring appropriate collection, storage,
transportation and processing of sputum samples, as well as
obtaining at least one early morning sample from the patient.
9) All the procedures aimed at obtaining samples for culture
and DST should be used whenever possible according to
evidence-based guidelines (sputum induction, bronchoscopy
and gastric lavage in children).
Standard 3 (replaces ISTC 3")
For all patients (adults, adolescents and children) suspected of
having extrapulmonary TB, appropriate specimens from the
suspected sites of involvement should be obtained for
microscopy, culture, DST and histopathological examination
in a quality-assured laboratory. In countries, settings or popu-
lations in which MDR-TB is suspected in a patient, rapid
testing for the identification of rifampicin and isoniazid
resistance in a quality-assured laboratory could be performed.
Notes
1) This third standard has been accordingly updated to be in
line with standards 1 and 2 with regard to essential, standard
diagnosis.
2) It is essential to obtain bacteriological confirmation from
extrapulmonary sites in order to confirm diagnosis and
consequently provide optimal and effective treatment; this
may include the more sensitive molecular test [4].
Standard 4 (replaces ISTC 4+)
All persons with chest radiographic findings suggestive of
pulmonary TB should have sputum specimens submitted for
microscopic examination, culture and DST in a quality-assured
laboratory. In countries, settings or populations in which
MDR-TB is suspected in a patient, rapid testing for the
identification of rifampicin resistance and when possible
isoniazid resistance in a quality-assured laboratory should be
performed.
Notes
1) This standard has been updated to be consistent with
the standards 1 and 2 with regard to essential, standard
diagnosis [4].
Standard 5 (ISTC 5 valid with an EU-adapted supplement)
The diagnosis of culture-negative pulmonary TB should be
based on the following criteria: all bacteriological tests are
negative (including direct sputum smear examinations, cul-
tures and rapid molecular testing); chest radiographic findings
are compatible with TB; and there is a lack of response to a trial
of broad spectrum antimicrobial agents (because the fluoro-
quinolones are active against M. tuberculosis complex and, thus,
may cause transient improvement in persons with TB, they
should be avoided). In persons who are seriously ill or have
known or suspected HIV infection or have any immune-
compromising conditions, the diagnostic evaluation should be
expedited and, if clinical evidence strongly suggests TB, a
course of anti-TB treatment should be initiated.
EU-adapted supplement
As the EU has adopted the culture-based case definition, the
main distinction of TB cases should be between culture-
positive and -negative cases, and not sputum smear status [5,
8, 11, 41].
In order to ensure quality diagnosis of both pulmonary and
extrapulmonary TB, adequate samples for bacteriological
examination should be obtained and processed using available
diagnostic tools (e.g. induced sputum, bronchoscopy and
bronchoalveolar lavage, and gastric washing) [4, 42–44], and
complemented by imaging (radiology, computed tomography
and magnetic resonance imaging) and other necessary exam-
inations performed according to evidence-based guidelines [4,
32, 35, 45, 46].
Culture, DST and rapid molecular testing should be performed
on each sample from both pulmonary and extrapulmonary TB,
including samples obtained through surgery or other invasive
procedures which usually undergo histological examinations
[5, 8, 11, 41].
Surgeons should be advised to save a biological specimen in
normal saline for microbiological and molecular biological
examinations and in formalin for histopathological examinations.
Notes
1) Other existing new diagnostic tools, e.g. additional nucleic
acid amplification techniques and other new techniques in the
development pipeline, after necessary validation has been
achieved, should be used within evidence-based diagnostic
algorithms and guidelines [19, 29, 46–54]. Before introducing
any new tool or approach, the evidence has to be validated and
have shown efficacy and patient value.
Standard 6 (ISTC 6 valid until specific EU paediatric
standards are available, with an EU-adapted supplement)
In all children suspected of having intrathoracic (i.e. pulmon-
ary, pleural, and mediastinal or hilar lymph node) TB,
bacteriological confirmation should be sought through exam-
ination of appropriate biological samples (by expectoration or
induced sputum, bronchial secretions, pleural fluid or gastric
washings) for smear microscopy, culture and DST in a quality-
assured laboratory. In the event of negative bacteriological
results, a diagnosis of TB should be based on the presence of
abnormalities consistent with TB on chest radiography or other
imaging, a history of exposure to an infectious case, evidence
of TB infection (positive tuberculin skin test (TST) and/or
interferon-c release assay (IGRA)) and clinical findings
suggestive of TB. For children suspected of having extra-
For all patients (adults, adolescents and children) suspected of
having extrapulmonary TB, appropriate specimens from the
suspected sites of involvement should be obtained for
microscopy, culture, DST and histopathological examination
in a quality-assured laboratory. In countries, settings or popu-
lations in which MDR-TB is suspected in a patient, rapid
testing for the identification of rifampicin and isoniazid
resistance in a quality-assured laboratory could be performed.
All persons with chest radiographic findings suggestive of
pulmonary TB should have sputum specimens submitted for
microscopic examination, culture and DST in a quality-assured
laboratory. In countries, settings or populations in which
MDR-TB is suspected in a patient, rapid testing for the
identification of rifampicin resistance and when possible
isoniazid resistance in a quality-assured laboratory should be
performed.
The diagnosis of culture-negative pulmonary TB should be
based on the following criteria: all bacteriological tests are
negative (including direct sputum smear examinations, cultures
nd rapid molecular testing); chest radiographic findings are
compatible wi h TB; and there s a lack of response o a trial f
broad spect um antimicrobial ag nts (be ause the fluoro-
quinolones are active against M. tubercul si complex and,
t us, may cause transient improvement in per ons with TB,
they should be avoi ed). In persons who r seriously ill or
have known or suspected HIV infection or have any immune-
compromisi g conditions, the iagno ic evaluation hould be
expedited and, if clinical evidence strongly suggests TB, a
course of anti-TB treatment should be initiated.
In all children suspected of having intrathoracic (i.e. pulmon-
ary, pleural, and mediastinal or hilar lymph node) TB,
bacteriological confirmation should be sought through exam-
ination of appropriate biological samples (by expectoration or
induced sputu , bronchial secretions, pleural fluid or gastric
washings) for smear microscopy, culture and DST in a quality-
assured laboratory. In the event of negative bacteriological
results, a diagnosis of TB should be based on the presence of
abnormalities consistent with TB on chest radiography or other
imaging, a history of exposure to an infectious case, evidence
of TB infection (positive tuberculin skin test (TST) and/or
interferon-c release assay (IGRA)) and clinical findings
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pulmonary TB, appropriate specimens from the suspected sites
of involvement should be obtained for microscopy and for
culture and histopathological examination.
EU-adapted supplement
Once TB is confirmed in a child, as defined previously,
standards 2–5 should be followed for complete diagnosis of the
case [4, 55].
Notes
1) With the exception of two clarifications (use of the term
‘‘appropriate biological samples’’; and for smear microscopy,
culture and DST in a quality-assured laboratory), this ESTC is
the same as the ISTC 6 for paediatric diagnosis [4].
2) ISTC 6 is valid until specific EU paediatric standards are
available.
3) Rapid DST testing could/should be considered in order to
obtain a rapid, preliminary diagnosis. However, research is
still ongoing to validate new molecular methods in this group.
STANDARDS FOR TB TREATMENT
Standard 7 (ISTC 7 valid)
Any practitioner treating a patient for TB is assuming an
important public health responsibility to prevent ongoing
transmission of the infection and the development of drug
resistance. To fulfil this responsibility the practitioner must not
only prescribe an appropriate regimen, but also utilise local
public and/or community health services, agencies and
resources when necessary, to perform contact investigation,
to assess the adherence of the patient and to address poor
adherence when it occurs.
Notes
1) The ISTC was maintained with the inclusion of naming the
need to involve community health services so as to highlight
the important role of civil society in patient treatment and
adherence [4, 56, 57].
Standard 8 (ISTC 8 valid with an EU-adapted supplement)
All patients (including those with HIV-infection) who have not
been previously treated and without any risk factors for drug
resistance should receive an internationally accepted first-line
treatment regimen using drugs of known bioavailability. The
initial phase should consist of two months of isoniazid,
rifampicin, pyrazinamide and ethambutol. The continuation
phase should consist of isoniazid and rifampicin given for four
months (2HRZE/4HR). The doses of anti-TB drugs used
should conform to international recommendations. Fixed dose
combinations of two (isoniazid and rifampicin), three (iso-
niazid, rifampicin and pyrazinamide) and four (isoniazid,
rifampicin, pyrazinamide and ethambutol) drugs are highly
recommended.
EU-adapted supplement
The selection of standardised regimens for WHO category I and
III patients (i.e. new pulmonary sputum smear-positive and new
sputum smear-negative/extrapulmonary cases) should be
performed according to international recommendations in
centres having the necessary expertise, as defined at the national
level and based on the number of cases managed every year and
other relevant parameters [4, 32, 35, 40, 58, 59]. The clinician
should ensure the correct drug regimen (including four active
drugs for the intensive phase of treatment) at the correct dose for
a sufficient duration. The daily dosage is recommended at least
during the intensive phase of treatment.
Based on confirmed DST results, treatment must be adapted
according to the drug-susceptibility pattern [4, 32, 34–37, 40,
58, 59].
Ideally, MDR-TB should be excluded in all TB cases.
Retreatment cases should be managed according to the
individual risk of MDR-TB until multi-drug resistance is
excluded [24, 33, 34, 36, 37, 60].
This standard has implications for the standards of diagnosis,
treatment and infection control.
Standard 9 (ISTC 9 valid)
To assess and foster adherence, a patient-centred approach to
administration of drug treatment, based on the patient’s needs
and mutual respect between the patient and the provider,
should be developed for all patients.
Supervision and support should be individualised and should
draw on the full range of recommended interventions and
available support services, including patient counselling and
education. A central element of the patient-centred strategy is
the use of measures to assess and promote adherence to the
treatment regimen and to address poor adherence when it
occurs. These measures should be tailored to the individual
patient’s circumstances, based on a detailed anamnesis of the
patient’s clinical and social history, and be mutually acceptable
to the patient and the provider. Such measures may include
direct observation of medication ingestion (directly observed
treatment) and identification and training of a treatment
supporter (for TB and, if appropriate, for HIV-infection) who
is acceptable and accountable to the patient and to the health
system. Appropriate incentives and enablers, including finan-
cial, social and psychosocial supports, may also serve to
enhance treatment adherence [4, 61, 62].
Standard 10 (ISTC 10 valid with an EU-adapted supplement)
Response to therapy in patients with pulmonary TB should be
monitored by follow-up smear microscopy and culture at the
time of completion of the initial phase of treatment (two
months for drug-susceptible TB). If the sputum smear and
culture are positive at completion of the initial phase, sputum
smears should be examined again at three months and, if
positive, drug susceptibility testing should be performed. In
patients with extrapulmonary TB and in children unable to
produce sputum, the response to treatment is assessed
clinically.
EU-adapted supplement
Treatment monitoring of MDR-TB cases should be performed
based on sputum smear and culture on a monthly basis [34].
The practices for treatment monitoring should be performed
according to international guidelines [40].
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Standard 11 (replaces ISTC 111, see also ESTC 1, 2 and 3)
An assessment of the likelihood of drug resistance, based on
history of prior treatment, exposure to a possible source
case having drug-resistant organisms and the community
prevalence of drug resistance, should be obtained for all
patients. Rapid testing, including rapid rifampicin and
isoniazid resistance testing should be performed for all
patients suspected of resistance as defined in standards 2
and 8. Furthermore, patient counselling and education should
begin immediately for all TB patients, in order to minimise the
potential for transmission. Infection control measures appro-
priate to the setting should be applied as recommended in
ESTC public health standard 20.
Notes
1) This standard emphasises the need to use the WHO-
recommended rapid molecular assays to rapidly rule out or
confirm suspicions of MDR-TB, as described in standards 2
and 8.
2) As expressed in standard 2, rapid molecular testing for
rifampicin and isoniazid resistance does not rule out the
requirement to perform standard DST to confirm results from
the molecular test as well as perform the comprehensive
standard DST.
Standard 12 (replaces ISTC 12e)
Patients with, or highly likely to have, TB caused by drug-
resistant (especially MDR/extensively drug-resistant (XDR)-
TB) organisms should be treated with specialised regimens
containing second-line anti-TB drugs. The regimen chosen may
be standardised or based on suspected or confirmed drug
susceptibility patterns. At least four drugs to which the
organisms are known, or presumed, to be susceptible to,
including an injectable agent and pyrazinamide, should be
used. Treatment should be given for at least 20 months, the
recommended intensive phase of treatment being 8 months
(instead of 6 months as in previous recommendations; see
below the EU adaptations for further detail).
EU-adapted supplement
As the treatment of MDR/XDR-TB often represents a last
chance to ensure patient cure and survival, a full range of
patient-centred measures, including counselling, observation
and support of treatment, as well as psychosocial support are
required to ensure adherence. This is particularly important
given that these patients often belong to socially and
economically disadvantaged groups.
For the treatment of MDR-TB, the addition of pyrazinamide to
a minimum of four second-line anti-TB drugs likely to be
"effective" is recommended, including the use of second-line
injectable drugs, as well as the use of fluoroquinolones (earlier
generations of fluoroquinolones, ciprofloxacin and ofloxacin,
are no longer recommended when later generation fluoroqui-
nolones, levofloxacin or moxifloxacin, are available) and
ethionamide (or prothionamide) and either cycloserine or p-
aminosalicylic acid if cycloserine cannot be used [34].
Second-line DST should be performed to confirm the drug
resistance pattern and to guide the correct choice of treatment.
Adverse events following prescription of second-line drugs
should be managed according to international recommenda-
tions with the aim to limit the probability of losing an effective
drug due to such adverse events [1–32].
Adverse events and the decision to start, modify or interrupt
a second-line regimen should ideally be managed by a team
of experts (e.g. ‘‘Consilium’’ or similar body) and not by
individual physicians, in order to minimise mistakes and share
responsibilities as well as share experience and expertise. All
efforts should be made to avoid development of additional
drug resistance [4, 36, 37, 63].
In addition to chemotherapy, surgery has proven to be
effective in selected cases [37].
Notes
1) In order to prevent the selection of resistant M. tuberculosis
mutants it is essential to treat with more than one effective
drug and a minimum of four effective drugs. It is therefore
essential not to add only one or two effective drugs to a failing
regimen [36, 64–75].
Standard 13 (ISTC 13 valid with an EU-adapted supplement)
A written record of all medications given, bacteriological
response and adverse reactions should be maintained for all
patients.
EU-adapted supplement
At the first contact with each patient, the complete clinical and
social history on TB should be collected and included in the
medical records. It should include the available information on
previous diagnosis, treatment (regimen, doses, duration and
changes in the regimen, etc.) and compliance, as well as
complete information on bacteriology at diagnosis and during
follow-up (sputum smear, culture and species identification,
drug susceptibility testing for first- and second-line drugs).
This information should be reported in the documentation
released to the patient (discharge letter, transfer-out form or
equivalent document) to facilitate continuum of care if the
patient is moved to another health unit [76, 77].
Notes
1) Reporting forms for the described documentation can be
obtained from several sources, some of which are listed here [2,
12, 41, 78].
STANDARDS FOR ADDRESSING HIV INFECTION AND
COMORBID CONDITIONS
Standard 14 (replaces ISTC 14**)
HIV testing and counselling should be recommended to all
patients with, or suspected of having, TB. Testing is of special
importance as part of the routine management of all patients in
areas with a high prevalence of HIV infection in the general
population and in patients with symptoms and/or signs of
HIV-related conditions. Because of the close relationship
between TB and HIV infection, integrated approaches to
prevention and treatment of both infections are recommended.
Notes
1) The aspect related to the setting and choice of offering HIV
testing was removed from the ESTC as it was deemed not
An assess ent of the likelihood of drug resistance, based on
history of prior treat ent, exposure to a possible source
case having drug-resistant organis s and the co unity
prevalence of drug resistance, should be obtained for all
patients. apid testing, including rapid rifa picin and
iso iazi resista ce testi g s o l be erfor e for all
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containing second-line anti-TB drugs. The regi en chosen ay
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relevant to the EU setting. Rather, in the EU it is considered
highly feasible to offer HIV testing to all TB patients.
Furthermore, it is considered important that integrated TB-
HIV management approaches be formed in the EU setting,
regardless of the prevalence [79–86].
Standard 15 (replaces ISTC 15##)
All patients with TB and HIV infection should be evaluated to
determine if antiretroviral therapy is indicated during the
course of treatment for TB, according to the severity of their
immunodeficiency. Appropriate arrangements for access to
antiretroviral drugs should be made for patients who meet
indications for treatment. However, initiation of treatment for
TB should not be delayed and the antiretroviral treatment
prescribed as soon as possible based on evidence.
Notes
1) The consideration of treatment with cotrimoxazole was
retracted from the ESTC as they refer to HIV management and
prevention of other infections. General prophylactic treatment
against other infections is not relevant in the EU setting.
Rather, the risk of HIV-related infections must be considered
individually for each patient based on risk factors and setting,
and form the basis for decisions to provide prophylactic
treatment against infections other than TB.
Standard 16 (ISTC 16 valid with an EU-adapted supplement)
Persons with HIV infection who, after careful evaluation, have
a positive test for presumed latent infection with M. tuberculosis
(LTBI) (TST and/or IGRAs) but do not have active TB should
be treated with isoniazid for 6–9 months or any new regimen
for which evidence becomes available.
EU-adapted supplement
In persons with known HIV infection in whom LTBI is
confirmed or highly probable, and in whom active TB is
excluded, LTBI preventive treatment with isoniazid should be
provided [84, 87–90].
As HIV infection is known to increase the probability of
developing TB disease upon infection, HIV-seropositive
persons who have been in contact of an index case harbouring
an MDR-TB strain, should undergo strict regular clinical
follow-up, allowing rapid initiation of specialised treatment
in case of disease development. While waiting for, or in the
absence of isolation of the responsible strain, the treatment
should be based on the index case’s drug-susceptibility pattern
(see also ESTC standards for diagnosis and treatment).
Strict clinical monitoring and no treatment of latent infection
should be provided if the index case is affected by an MDR-TB
strain [4].
The ESTC above should also be applicable for persons with
comorbidities or on treatments that increase the risk for TB
reactivation.
Notes
1) Comorbidities for reactivation of TB, other than HIV
infection, encompass conditions that decrease the host immune
response, some of which are: diabetes mellitus, treatment with
tumour necrosis factor (TNF)-antagonists, cancer chemother-
apy and treatment with high-dose corticosteroids, etc. [90, 91].
Standard 17 (ISTC 17 valid with an EU-adapted supplement)
All providers should conduct a thorough assessment of
conditions that could affect TB treatment response or outcome.
At the time the case management plan is developed, the
provider should identify additional services that would
support an optimal outcome for each patient and incorporate
these services into an individualised plan of care. This plan
should include assessment of, and referrals for treatment, of
other illnesses with particular attention to those known to
affect treatment outcome, for instance care for diabetes
mellitus, drug and alcohol treatment programmes, tobacco
smoking cessation programmes and other psychosocial sup-
port services, or to such services as antenatal or well-baby care.
EU-adapted supplement
Implementation of the entire package described in the WHO
interim policy on collaborative TB/HIV activities should be
performed for all the activities, both those covered here and in
the remaining WHO package [79, 80, 82–84].
STANDARDS FOR PUBLIC HEALTH AND TB
PREVENTION
Standard 18 (ISTC 18 valid with an EU-adapted supplement)
All providers of care for patients with TB should ensure that
persons who are in close contact with patients who have
infectious TB (e.g. in families, congregate settings like migrants
shelters, schools and prisons), are evaluated and managed in
line with international recommendations.
The risk of TB transmission depends on the concentration of
the mycobacteria in the air, the duration of the contact and the
susceptibility of the contact to infection and disease. The
determination of priorities for contact investigation is based on
the likelihood that a contact: 1) has undiagnosed TB; 2) is at
high risk of having been infected by the index case; 3) is at high
risk of developing TB if infected; and 4) is at risk of having
severe TB if the disease develops.
EU-adapted supplement
Individuals undergoing treatment with TNF-antagonists
should be considered as high-risk contacts. According to
ESTC number 16, in individuals who are HIV infected or
affected by comorbidities, treatment of latent infection should
be promptly initiated if TB infection is identified by TST and/
or IGRAs and active TB disease is excluded [92–96]. In case of
contact with an MDR-TB index case, strict clinical monitoring
should be provided, as there is no evidence that treatment of
latent infection with available drugs is presently effective.
Notes
1) The bullets listing the levels of priority for initiating contact
investigation as described in the ISTC have been removed from
the ESTC, as they were considered not to be relevant for the EU
setting. Rather, an introductory sentence was added stating the
determinants of TB transmission that should be considered
when assessing whether transmission has occurred and the
need for initiating contact tracing [46, 60, 94, 95, 97].
Standard 19 (ISTC 19 valid with an EU-adapted supplement)
Children under 5 yrs of age and persons of any age with HIV
infection who are close contacts of an infectious index patient
and who, after careful evaluation, do not have active TB,
All patients with TB and HIV infection should be evaluated to
deter ine if antiretroviral therapy is indicated during the
course of treat ent for TB, according to the severity of their
i unodeficiency. Appropriate arrange ents for access to
antiretroviral drugs should be ade for patients who eet
indications for treat ent. However, initiation of treat ent for
TB should not be delayed and the antiretroviral treat ent
prescribed as soon as possible based on evidence.
Persons with HIV infection who, after careful evaluation, have
a positive test for presumed latent infection with . tuberculosis
(LTBI) (TST and/or IGRAs) but do not have active TB should
be treated with isoniazid for 6–9 months or any new regimen
for which evidence becomes available.
ll providers should conduct a thorough assess ent of
conditions that could affect TB treat ent response or outco e.
t the ti e the case anage ent plan is developed, the
provider should identify additional services that ould
support an opti al outco e for each patient and incorporate
these services into an individualised plan of care. This plan
should include assess ent of, and referrals for treat ent, of
other illnesses ith particular attention to those kno n to
affect treat ent outco e, for instance care for diabetes
ellitus, drug and alcohol treat ent progra es, tobacco
s oking cessation progra es and other psychosocial sup-
port services, or to such services as antenatal or ell-baby care.
All providers of care for patients with TB should ensure that
persons who are in close contact with patients who have
infectious TB (e.g. in fa ilies, congregate settings like igrants
shelters, schools and prisons), are evaluated and anaged in
line with international recommendations.The risk of TB
transmission depends on the concentration of the mycobacteria
in the air, the duration of the contact and the susceptibility of
the contact to infection and disease. The determination of
priorities for contact investigation is based on the likelihood
that a contact: 1) has undiagnosed TB; 2) is at high risk of
having been infected by the index case; 3) is at high risk of
developing TB if infected; and 4) is at risk of having severe TB
if the disease develops.
Children under 5 yrs of age and persons of any age with HIV
infection who are close contacts of an infectious index patient
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should be treated for presumed latent TB infection with
isoniazid.
EU-adapted supplement
As per previous ESTC, strict clinical monitoring and no
treatment of latent infection should be provided if the index
case is affected by an MDR-TB strain [4].
Clinicians should collaborate with public health authorities in
implementing adequate contact tracing procedures, performed
according to national and international recommendations on
progressive circles, when an infectious index case is diagnosed
and notified [94, 98–100].
Notes
1) Preventive treatment for presumed latent TB infection
should be according to national and international recommen-
dations [87, 89].
Standard 20 (ISTC 20 valid with an EU-adapted supplement)
Each healthcare facility caring for patients who have, or are
suspected of having infectious TB, should develop and
implement an appropriate TB infection control plan.
EU-adapted supplement
Clinicians should ensure that all newly admitted patients who
are suspected of having infectious TB are subject to respiratory
isolation until their diagnosis is confirmed and excluded [4].
In order to prevent transmission of mycobacteria to other
patients, staff and/or visitors and smear-positive TB patients
should ideally be isolated in appropriate rooms until they
achieve bacteriological conversion (negative-sputum micro-
scopy). Patients suspected of having TB (if feasible) and MDR-
TB patients (strongly recommended) should be isolated in
negative-pressure ventilation rooms.
An appropriate infection control plan, managed by a desig-
nated person, should include the following four components:
managerial activities, administrative controls, environmental
controls and personal protection interventions [97]. Adequate
administrative measures for TB infection control should be in
place in all healthcare facilities, as well as adequate respiratory
protection measures (including the use of respirators following
respirator fit testing for staff and the use of surgical mask for
infectious patients). Appropriate training on infection control
to staff, and standardised health education of patients on
cough etiquette, based on validated tools, should also be
included in the infection control plan. Infection control
committees, which cover airborne diseases, and includes
infection control experts, should also be implemented [60, 97].
Notes
1) The implementation of an infection control plan is essential
for the treating clinician, health facility and the overall health
system. Clinicians should maintain dialogue within their
health facility; develop a sound infection control plan, and
their technical expertise. The health facility should engage with
all healthcare workers, non-medical staff, patients and visitors
and ensure optimal implementation, practice and monitoring
of these infection control measures; all healthcare workers
should be (re)trained in the infection control plan [4, 38, 97,
101].
2) With regard to the need of isolating infectious TB patients, it
is important to consider several options for isolation, and not
only that of hospitalisation. For example, a patient with drug-
susceptible TB that can be treated at home (i.e. no need for
hospitalisation due to severe health status), does not need to be
hospitalised, as long as appropriate measures for treatment
and infection control are ensured at the residence [97, 102, 103].
3) Patients with a clinical indication for hospital admission,
such as comorbidities, should not be hospitalised in a general
medical ward. Ideally such patients should be placed in rooms
that allow appropriate respiratory isolation. It is therefore
important to have a designated infection control focal person
with the required authority to ensure implementation of the
infection control plan.
Standard 21 (ISTC 21 valid with an EU-adapted supplement)
All providers must report both new and retreatment TB cases
and their treatment outcomes to local public health authorities,
in conformance with applicable legal requirements and
policies.
EU-adapted supplement
Clinicians should perform treatment outcome evaluations in
their clinical unit at regular time intervals (e.g. quarterly) [6,
104, 105]. Treatment outcomes should be reported to local
public health authorities, in conformance with applicable
requirements and policies and, at the same time be used as a
monitoring and evaluation tool to improve the quality of
patient management. Information on treatment outcome
should also regularly be channelled back from the public
health department to the healthcare providers, to allow a
coordinated evaluation of the outcomes. Information on the
final outcome of patients should be available at the clinical unit
which initiated treatment, even when the patient is transferred
out. Adequate training must be provided to health staff in
charge of reporting treatment outcomes to public health
authorities and performing the quarterly evaluation of own
cases. This principle is also applicable to TB patients moving
across the EU borders [5, 13, 25, 106, 107].
SUPPORTING ENABLERS TO THE ESTC
In the process of developing the standards and reaching a
consensus, the panel of experts identified the need and added
value of identifying and listing supporting enablers to the
standards. These are a resource for policy makers, clinicians,
public health workers and other stakeholders to identify how
best to adopt, adapt, introduce and implement the ESTC in
their setting with the ultimate goal of securing optimal TB care,
prevention and control [2, 4, 12, 38, 60]. They are as follows:
1) Formal adoption of the European Standards for Tuberculosis
Care, for the care, prevention and control, ideally translated
into the country-specific language(s) after their endorsement
by national medical associations. Ideally the ESTC should be
incorporated into training curricula of health staff [108].
2) Development of consistent TB control and elimination
strategies and policies according to the principles described in
and who, aft r careful eval ation, do not have active TB,
should be treated for presumed latent TB infection with
isoniazid.
Each healthcare facility caring for patients who have, or are
suspected of having infectious TB, should develop and
implement an appropriate TB infection control plan.
ll rovi ers st re ort bot e a retreat e t cases
a t eir treat e t o tco es to local blic ealt a t orities,
i co for a ce it a licable legal req ire e ts a
olicies.
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the new European Framework [7] and the Framework action
plan to fight TB in the EU and its follow-up [109–112].
3) Adoption of specific, updated, evidence-based TB and
MDR-TB guidelines, together with mechanisms to update
them on a regular basis and to monitor their implementation
(audit- and or knowledge, attitudes and practices study-based)
[63, 113, 114].
4) Planning and organisation of an adequate national labora-
tory network to ensure that a minimum and sufficient number
of mycobacteriology laboratories are in place, allowing
implementation of the standards described in this document
(adequate coverage of the country, adequate internal and
external quality assurance procedures in place, sufficient
numbers of samples per laboratory to ensure proficiency,
availability of national laboratories with reference functions to
support regional and local laboratories etc.).
5) Development of policies ensuring a continuous availability
of all first- and second-line TB drugs (e.g. through coordinated
procurement with partner countries for the drugs not
registered in the country or which are necessary in small
quantities) [19, 110, 115].
6) Securing consistent and adequate funding for TB and MDR/
XDR-TB care, prevention and control that is sufficient to run the
activities mentioned in this document. This should include
psychosocial support and coordination of care for all patients, as
highlighted in the International Patients’ Charter for rights to
diagnosis and treatment. This applies particularly to patients
belonging to vulnerable populations [57, 107, 116–118].
REPLACED ISTC
*ISTC 1: all persons with otherwise unexplained productive
cough lasting 2–3 weeks or more should be evaluated for TB.
#ISTC 2: all patients (adults, adolescents and children who are
capable of producing sputum) suspected of having pulmonary
TB should have at least two sputum specimens submitted for
microscopic examination in a quality-assured laboratory.
When possible, at least one early morning specimen should
be obtained.
"ISTC 3: for all patients (adults, adolescents and children)
suspected of having extrapulmonary TB, appropriate speci-
mens from the suspected sites of involvement should be
obtained for microscopy, culture and histopathological exam-
ination.
+ISTC 4: all persons with chest radiographic findings sugges-
tive of TB should have sputum specimens submitted for
microbiological examination.
1ISTC 11: an assessment of the likelihood of drug resistance,
based on history of prior treatment, exposure to a possible
source case having drug-resistant organisms and the commu-
nity prevalence of drug resistance, should be obtained for all
patients. DST should be performed at the start of therapy for
all previously treated patients. Patients who remain sputum
smear-positive at completion of three months of treatment and
patients who have failed, defaulted from, or relapsed following
one or more courses of treatment should always be assessed
for drug resistance. For patients in whom drug resistance is
considered to be likely, culture and testing for susceptibility/
resistance to at least isoniazid and rifampicin should be
performed promptly. Patient counselling and education
should begin immediately to minimise the potential for
transmission. Infection control measures appropriate to the
setting should be applied.
eISTC 12: patients with, or highly likely to have, TB caused by
drug-resistant (especially MDR/XDR) organisms should be
treated with specialised regimens containing second-line anti-
TB drugs. The regimen chosen may be standardised or based
on suspected or confirmed drug susceptibility patterns. At
least four drugs to which the organisms are known or
presumed to be susceptible, including an injectable agent,
should be used and treatment should be given for at least 18–
24 months beyond culture conversion. Patient-centred mea-
sures, including observation of treatment, are required to
ensure adherence. Consultation with a provider experienced in
treatment of patients with MDR/XDR-TB should be obtained.
**ISTC 14: HIV testing and counselling should be recom-
mended to all patients with, or suspected of having, TB.
Testing is of special importance as part of routine management
of all patients in areas with a high prevalence of HIV infection
in the general population, in patients with symptoms and/or
signs of HIV-related conditions, and in patients having a
history suggestive of a high risk of HIV exposure. Because of
the close relationship between TB and HIV infection, in areas
of high HIV prevalence integrated approaches to prevention
and treatment of both infections are recommended.
##ISTC 15: all patients with TB and HIV infection should be
evaluated to determine if antiretroviral therapy is indicated
during the course of treatment for TB. Appropriate arrange-
ments for access to antiretroviral drugs should be made for
patients who meet indications for treatment. However, initia-
tion of treatment for TB should not be delayed. Patients with
TB and HIV infection should also receive cotrimoxazole as
prophylaxis for other infections.
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